Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.41 |
| ▸ | DRD3 | P35462 | 6/20 | 0.41 |
| ▸ | DRD1 | P21728 | 5/20 | 0.41 |
| ▸ | DRD5 | P21918 | 4/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 4/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | PRKCI | P41743 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245289 | 0.82 | DRD2 (0.44) | DRD2DRD3DRD1DRD5OPRK1 | |
| SCHEMBL586165 | 0.75 | HTR2A (0.45) | DRD4 | |
| SCHEMBL14317167 | 0.70 | DRD1 (0.61) | DRD2DRD3DRD1DRD5OPRK1 | |
| SCHEMBL30672580 | 0.70 | — | — | |
| SCHEMBL8408108 | 0.70 | — | — | |
| SCHEMBL21318766 | 0.70 | — | — | |
| SCHEMBL577455 | 0.70 | PNMT (0.42) | — | |
| SCHEMBL788852 | 0.69 | HSD17B1 (0.64) | DRD2DRD3DRD1DRD5DRD4 | |
| Ammonia Solution, Strong SCHEMBL21632258 | 0.69 | DRD2 (0.54) | DRD2DRD3DRD1DRD5OPRK1 | |
| SCHEMBL29439100 | 0.69 | HSD17B1 (0.64) | DRD2DRD3DRD1DRD5DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109843379-B | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2022-12-30 | — | — | CN | claimed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | claimed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | claimed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | claimed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | claimed |
| CN-109843379-B | Substituted ureas and methods of making and using the same | 梅比斯发现公司 | 2022-12-30 | — | — | CN | disclosed |
| US-11198685-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | MEBIAS DISCOVERY, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10683283-B2 | Substituted ureas and methods of making and using same | MEBIAS DISCOVERY, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3506983-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | Mebias Discovery LLC (US) | 2019-07-10 | — | — | EP | disclosed |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC | 2019-06-27 | — | — | US | disclosed |
| WO-2018045229-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | MEBIAS DISCOVERY LLC (US) | 2018-03-08 | — | — | WO | disclosed |
| EP-2461811-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX Pharmaceuticals, Inc. (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-2417134-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX Pharmaceuticals, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2011017389-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS USEFUL AGAINST VIRAL INFECTIONS, PARTICULARLY HCV | IDENIX PHARMACEUTICALS, INC. (US) | 2011-02-10 | — | — | WO | disclosed |
| WO-2010118078-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| EP-0313081-B1 | 2-Oxa-isocephem compounds, compositions containing the same and processes for preparing the same | OTSUKA PHARMA CO LTD (JP) | 1994-02-02 | — | — | EP | disclosed |
| US-4950662-A | ANTIBIOTIC | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683283-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | DRD2 3348/4885DRD3 2618/4885DRD1 3621/4885 |
| US-20190194178-A1 | SUBSTITUTED UREAS AND METHODS OF MAKING AND USING SAME | UMPS, METTL3, UTS2R | DRD2 3348/4885DRD3 2618/4885DRD1 3621/4885 |
| US-11198685-B2 | Substituted ureas and methods of making and using same | UMPS, METTL3, UTS2R | DRD2 3348/4885DRD3 2618/4885DRD1 3621/4885 |
| US-20200308155-A1 | Substituted Ureas and Methods of Making and Using Same | UMPS, METTL3, UTS2R | DRD2 3348/4885DRD3 2618/4885DRD1 3621/4885 |
| US-20110129443-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | DRD2 4735/4885DRD3 4654/4885DRD1 4699/4885 |
| US-20100260710-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | DRD2 4735/4885DRD3 4654/4885DRD1 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.